Tandem Diabetes Care TNDM United States — Sales

Similar metrics at other companies

ATROUnited States — Sales

$153.77M+3.6%

GTL

GTLSUnited States — Sales

$449.33M+8.3%

OLNUnited States — Sales

$1.15B+0.8%

NVSTUnited States — Sales

$320.33M+6.5%

DXPEUnited States — Sales

$555.19M+15.9%

VNTUnited States — Sales

$527.8M+1.5%

FAQ

What is Tandem Diabetes Care's united states — sales?

Tandem Diabetes Care (TNDM) reported united states — sales of $179.29M in Q2 2026.

How has Tandem Diabetes Care's united states — sales changed year-over-year?

Tandem Diabetes Care's united states — sales increased by 5.3% year-over-year, from $170.21M to $179.29M.

What is the long-term trend for Tandem Diabetes Care's united states — sales?

Over 4 years (2021 to 2025), Tandem Diabetes Care's united states — sales has grown at a 7.7% compound annual growth rate (CAGR), from $524.91M to $706.94M.

What does united states — sales mean?

This metric represents the total revenue generated from the sale of medical devices and related supplies within the United States geographic market. It serves as a primary indicator of market penetration and demand for the company's insulin delivery technology in its largest operating region. Tracking this figure helps investors assess the company's ability to maintain its competitive position and capture market share within the domestic healthcare landscape.